Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Allogeneic Stem Cell Transplants Using Chord Blood Expands Possible Donor Options For Multiple Myeloma Patients

Home/Uncategorized/Allogeneic Stem Cell Transplants Using Chord Blood Expands Possible Donor Options For Multiple Myeloma Patients

Allogeneic Stem Cell Transplants Using Chord Blood Expands Possible Donor Options For Multiple Myeloma Patients

Here is a research abstract I found on the OncologyStat.com site, confirming how using chord blood can be a good allogeneic stem cell transplant alternative:
Allogeneic Hematopoietic Cell Transplantation for Hematological Malignancy: Relative Risks and Benefits of Double Umbilical Cord Blood

Blood. 2010 Aug 4;[Epub Ahead of Print], CG Brunstein, JA Gutman, DJ Weisdorf, AE Woolfrey, TE Defor, TA Gooley, MR Verneris, FR Appelbaum, JE Wagner, C Delaney

ABSTRACT

Effectiveness of double umbilical cord blood (dUCB) grafts relative to conventional marrow and mobilized peripheral blood from related and unrelated donors has yet to be established. We studied 536 patients at the Fred Hutchinson Cancer Research Center and University of Minnesota with malignant disease who underwent transplant with an HLA matched related donor (MRD, n=204), HLA allele matched or 1-antigen mismatched unrelated adult donor (MUD, n=152; MMUD, n=52) or 4-6/6 HLA matched dUCB (n=128) graft after myeloablative conditioning. Leukemia-free survival (LFS) at 5 years was similar for each donor type (dUCB 51% [95%CI, 41-59%]; MRD 33% [95%CI, 26-41%]; MUD 48% [40-56%]; MMUD 38% [95%CI, 25-51%]). The risk of relapse was lower in recipients of dUCB (15%, 95%CI, 9-22%) compared to MRD (43%, 95%CI, 35-52%), MUD (37%, 95%CI, 29-46%) and MMUD (35%, 95%CI, 21-48%), yet non-relapse (NRM) was higher for dUCB (34%, 95%CI, 25-42%); MRD (24% (95%CI, 17-39%) and MUD (14%, 95%CI, 9-20%). We conclude that LFS after dUCB transplantation is comparable to that observed after MRD and MUD transplantation. For patients without an available HLA matched donor, the use of two partially HLA matched UCB units is a suitable alternative.

Could allogeneic SCTs be the next, best option for multiple myeloma patients?  Using chord blood seems to be safer and offer fewer rejection risks.   A friend of mine, Steve, was out of treatment options.  Docs used chord blood from a baby in the UK.  He has some significant side-effects from his host-graft meds, but is alive, well and working today.  I write about Steve’s transplant ordeal in my first book, Living with Multiple Myeloma.

Feel good and keep smiling!  Pat